baloxavir

Baloxavir (S-033447) is a first-in-class cap-dependent endonuclease inhibitor of the influenza virus polymerase PA subunit.

Baloxavir marboxil (S-033188) is a novel cap-dependent endonuclease inhibitor designed for the treatment of influenza A and B virus infections.

Baloxavir-d1 is a deuterium-labeled form of Baloxavir. Baloxavir (Baloxavir acid), derived from the precursor Baloxavirmarboxil, is a pioneering and selective inhibitor of the cap-dependent endonuclease (CEN) within the polymerase PA subunit of both influenza A and B viruses. It impedes viral RNA transcription and replication, exhibiting potent antiviral activity.

Baloxavir-D5 is the deuterated form of Baloxavir. Baloxavir (T14495) (Baloxavir acid), derived from the prodrug Baloxavir (T14495) marboxil, acts as a first-in-class, effective, and selective cap-dependent endonuclease (CEN) inhibitor targeting the PA subunit of influenza A and B virus polymerase. It inhibits the transcription and replication of viral RNA, demonstrating potent antiviral activity.